Drug Trial Radar · NCT06970301
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 28, 2025
Primary completion
May 29, 2026
Study completion May 29, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.
Conditions
- Healthy Study Participants
Interventions
glovadalenDrug
Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.
PlaceboOther
Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of TEAEs (Part A)Time frame: From Baseline to the end of Safety Follow-up Period (up to 49 days)
- Occurrence of TEAEs (Part B)Time frame: From Baseline to the end of Safety Follow-up Period (up to 44 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Up0135 1001
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.